Integrin-Synapse Adhesion Modulation Therapy targets the cell adhesion molecules that mediate synaptic structure, stability, and signaling at neuronal synapses. This therapeutic approach aims to restore integrin-mediated adhesion that is diminished in neurodegenerative diseases, thereby stabilizing synaptic connections and promoting structural plasticity.
Integrins are heterodimeric transmembrane receptors (α/β subunits) that connect the extracellular matrix to the actin cytoskeleton. In the brain, neuronal integrins (particularly α3β1, α5β1, α6β1, αvβ3) are enriched at synapses where they regulate spine formation, synaptic transmission, and plasticity@chan2010.
Multiple lines of evidence implicate integrin dysfunction in neurodegenerative diseases:
Alzheimer's Disease: Aβ oligomers disrupt integrin signaling and reduce α5β1 expression at synapses. Integrin-mediated adhesion is essential for spine stability—loss leads to dendritic spine collapse@shi2016.
Parkinson's Disease: Integrin-linked kinase (ILK) activity is reduced in PD brain. αvβ3 and α5β1 integrins regulate dopaminergic neuron survival and process outgrowth.
ALS: Integrin signaling is impaired at neuromuscular junctions. α7β1 integrin protects motor neurons from excitotoxic cell death.
FTD: TDP-43 pathology disrupts integrin gene expression. Synaptic adhesion molecules are downregulated in FTD brain.
Neuronal integrins interact with:
This integration makes integrins central hubs for synaptic stability and activity-dependent remodeling@naka2013.
Integrin-Synapse Modulation works through several complementary mechanisms:
Small molecules or peptides that activate integrin signaling:
Target downstream effectors:
Enhance ligand availability:
AAV-mediated expression:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | Integrin-synapse modulation underexplored for neurodegeneration; distinct from existing FAK inhibition approach |
| Mechanistic Rationale | 8 | Strong preclinical data on integrin-spine relationship; Aβ disrupts integrin signaling |
| Root-Cause Coverage | 7 | Addresses synaptic structural failure, not just protein aggregation |
| Delivery Feasibility | 6 | Small molecules and peptides available; CNS penetration moderate |
| Safety Plausibility | 8 | Integrins have well-characterized biology; isoform selectivity important |
| Combinability | 9 | Synergistic with synaptic resilience approaches, BDNF, and neuroprotective compounds |
| Biomarker Availability | 7 | Integrin phosphorylation (p-FAK), spine morphology metrics |
| De-risking Path | 7 | Need integrin isoform selectivity; dose-response optimization |
| Multi-disease Potential | 8 | AD, PD, ALS, FTD all involve synaptic integrin dysfunction |
| Patient Impact | 8 | Synaptic loss directly correlates with cognitive decline |
Total Score: 75/100
| Disease | Rationale | Coverage Score |
|---|---|---|
| Alzheimer's Disease | Aβ disrupts α5β1 integrin; spine instability | 8 |
| Parkinson's Disease | ILK deficiency in dopaminergic neurons | 7 |
| ALS | α7β1 protects motor neurons; NMJ instability | 7 |
| Frontotemporal Dementia | TDP-43 reduces integrin expression | 6 |
| Aging | Integrative decline with normal aging | 8 |